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Over the last decades, vaccine development has advanced significantly in pursuing
higher safety with less side effects. However, this is often accompanied by a reduction
in vaccine immunogenicity and an increased dependency on adjuvants to enhance
vaccine potency. Especially for diseases like cancer, it is important that therapeutic
vaccines contain adjuvants that promote strong T cell responses. An important mode
of action for such adjuvants is to prolong antigen exposure to dendritic cells (DCs)
and to induce their maturation. These mature DCs are extremely effective in the
activation of antigen-specific T cells, which is a pre-requisite for induction of potent and
long-lasting cellular immunity. For the activation of CD8+ cytotoxic T cell responses,
however, the exogenous vaccine antigens need to gain access to the endogenous
MHCI presentation pathway of DCs, a process referred to as antigen cross-presentation.
In this review, we will focus on recent insights in clinically relevant vaccine adjuvants
that impact DC cross-presentation efficiency, including aluminum-based nanoparticles,
saponin-based adjuvants, and Toll-like receptor ligands. Furthermore, we will discuss
the importance of adjuvant combinations and highlight new developments in cancer
vaccines. Understanding the mode of action of adjuvants in general and on antigen
cross-presentation in DCs in particular will be important for the design of novel adjuvants
as part of vaccines able to induce strong cellular immunity.
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INTRODUCTION
Since the development of the first successful vaccine by Edward Jenner in 1796 against smallpox,
a lot of research has been done on the development of vaccines against other diseases. Current
vaccines against infectious agents can be divided into live attenuated vaccines (where their virulent
properties are weakened, e.g., yellow fever, measles), subunit vaccines (containing a fragment of
the pathogen, e.g., Hepatitis B), toxoid vaccines (with inactivated toxic compounds, e.g., tetanus,
diphtheria), and conjugated vaccines (linking polysaccharide coats to protein, e.g., Haemophilus
influenzae type B) (1). While especially prophylactic vaccines against infectious diseases have been
developed successfully and are clinically applied, development of therapeutic vaccines against
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persistent infections or cancer is lagging behind. For the
development of new vaccines many aspects should be taken into
consideration such as the nature of the antigenic material, the
type of immune memory responses that needs to be induced,
but also the administration and delivery routes, which might
reduce the risk of side effects. Next generation vaccines like
subunit vaccines for infectious diseases mostly aim for higher
safety with less side effects, which is often detrimental for their
immunogenicity. Therefore, adjuvants are usually required to
enhance vaccine potency. Similarly, tumor neoantigen vaccines
are devoid of immune activation potential and are fully
dependent on strong adjuvants to induce protective immune
responses. Adjuvants generally act by activating innate and
adaptive immune responses, but can also function to create
an antigen depot, slowly releasing the antigen for prolonged
presentation and stimulation of the immune system (2). One
of the first licensed carrier-adjuvants was alum, an inorganic
adjuvant widely used in vaccines against e.g., hepatitis B virus,
human papillomavirus, and diphtheria. Like most of the early
adjuvants, they were mainly aimed at inducing protective
antibody responses and hence strongly Th2 biased immunity.
The discovery of microbe sensing pattern recognition receptors
(PRRs), such as Toll-like receptors (TLRs) and nucleotide-
binding oligomerization domain (NOD)-like receptors, has
boosted research into vaccine adjuvants aiming to induce
cellular immune responses that are essential to fight intracellular
pathogens and cancer cells. Interaction of PRR with their
corresponding ligands potentiate and shape the adaptive immune
responses (3). Since then, several types of immune potentiating
adjuvants (e.g., TLR agonists and saponin QS-21) have been
licensed and used in the clinic against various diseases (Table 1).
Each adjuvant has a unique immunological signature that
can be used in highly different types of diseases. Choosing the
right adjuvant to combine with the best target antigen for a
given disease is a challenging task (12). Next generation vaccine
adjuvants are now mostly designed to contain both the function
of a carrier and a potent immune response inducer to boost the
efficacy of the vaccine. Although many prophylactic vaccines rely
on neutralizing antibody responses, especially diseases such as
cancer, HIV, tuberculosis, and malaria are in need of a vaccine
eliciting strong T cell responses (13–17). As a consequence, many
studies investigated the potency of next generation adjuvants
for their capacity to induce antigen specific CD8+ and CD4+
T cell responses. An important characteristic of adjuvants able
to induce cellular immunity is the efficient delivery of the
target antigen into professional antigen presenting dendritic cells
(DCs) and its potency in activating these DCs. In general, DC
maturation enhances their antigen presentation capacity and
ability to activate T cells and is a prerequisite for induction
of potent and long-lasting immunity. One of the best studied
DC maturation stimuli are TLR ligands, including poly(I:C),
LPS, CpG, R848, and Pam3CSK4, which can activate DCs to
upregulate co-stimulatory molecules such as CD40, CD80, and
CD86 (18). TLRs can be expressed extracellularly (TLRs 1, 2,
4, 5, and 6) and intracellularly (TLRs 3, 7, 8, and 9) (3). All
TLRs, except TLR3, utilize the adaptor molecule MyD88 to
trigger activation of TGF-β Activated Kinase 1 which activates
MAPK and NF-κB signaling resulting in TNF-α, IL-12, and
IL-6 production (19, 20). Intracellular TLRs, which are mostly
found in endosomes, require internalized ligands such as nucleic
acids to activate downstream signaling. Currently, only the TLR4
agonist monophosphoryl lipd (MPL), a non-toxic LPS-derived
TLR4 ligand, is approved for human applications (Table 1).
Other TLR ligands showed effective tumor immunity in animal
models or clinical trials (21–23).
Alternative pathways for DC maturation include intracellular
receptors, such as Nucleotide binding domain-Like Receptor
Protein 3 (NLRP3), which forms a caspase-1 activating
complex (inflammasome) together with Cardinal and apoptosis-
associated speck-like protein containing a caspase recruitment
domain (24). This pathway results in cleavage and release of
the pro-inflammatory cytokines IL-1β, IL-18, and IL-33 (25). A
very important characteristic of adjuvants that has receivedmuch
less attention is their ability to induce presentation of exogenous
antigens not only in MHCII to CD4+ T cells but also in MHCI
to CD8+ T cells. This latter process is essential for efficient CD8+
T cell priming and is called antigen cross-presentation. In this
review, we will focus on recent insights in clinically relevant
adjuvants that impact DC cross-presentation. Understanding DC
cross-presentation will be important to design novel adjuvants
able to induce strong cellular immunity for future vaccine
development.
MOLECULAR MECHANISMS OF
DENDRITIC CELL CROSS-PRESENTATION
Dendritic cells are the professional APCs of our immune
system that are key in linking innate and adaptive immunity.
DCs are especially known for their ability to cross-present,
as they process and present exogenous antigens on MHCI
molecules much more efficiently than other phagocytes. The
efficiency of CD8+ T cell priming called cross-priming by
DCs is dependent on both antigen cross-presentation efficiency
(number of a given MHCI/peptide complex on the cell surface)
and the level of DC maturation (expression levels of co-
stimulatory molecules and cytokines). It has been reported that
cross-presentation is important for inducing T cell responses
specific for tumor antigens and infectious diseases (26–28).
How exogenous antigens are processed in DCs and presented
on MHCI to CD8+ T cells is still not fully understood. Two
main pathways of antigen cross-presentation in DCs have been
proposed: the cytosolic pathway and the vacuolar pathway. In
the cytosolic pathway, exogenous antigens or protein fragments
derived from it are transported from endosomal vesicles into the
cytosol where they are degraded by the proteasome. The trimmed
peptides are then transported by the transporter associated with
antigen processing (TAP) to the endoplasmic reticulum (ER)
where they are loaded on MHCI molecules (29–31). However,
there have been suggestions that the protein fragments can be
transported back into endocytic compartments and trimmed by
insulin-regulated aminopeptidase (IRAP) and loaded on MHCI
(32). In the vacuolar pathway antigens are degraded by proteases
in endo/lysosomal compartments and directly loaded on MHCI
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TABLE 1 | Clinically approved adjuvants.
Adjuvant Description Proposed immune mechanism Clinical application
Aluminum salts Hydroxide, phosphate, alum Activation of NLRP3 inflammasome and caspase-1 in
DCs, induces Th2 response (4, 5).
HBV, HPV, diphtheria, and tetanus
AS01 Liposome (containing MPL
and QS-21)
Activates APCs expressing TLR4, stimulates cytokine
and co-stimulatory molecules production, promotes
antigen-specific antibody responses and stimulates
CD8+ T cells (6).
Malaria, Herpes Zoster
AS02 Oil-in-water emulsion
(containing MPL and QS-21)
Antigen specific CD8+ and CD4+ T cell responses and
antibody responses (7)
Malaria
AS03 Oil-in-water emulsion
(containing squalene,
polysorbate 80 and
α-tocopherol)
NF-κB activation, production of cytokines and
chemokines in muscle and draining LN, provoke
migration of monocytes, DCs and granulocytes into
draining LN, enhancing CD4+ T cell immune responses
(8).
Pandemic influenza
AS04 MPL formulated in
aluminum salt
Activates TLR4 on DCs, induction of cytokines and
antigen specific T cell activation (9).
HBV, HPV
MF59 Oil-in-water emulsion Rapid influx of CD11b+ cells, upregulation of
inflammatory cytokines and chemokines, recruitment of
APCs (10).
Seasonal and pandemic influenza
Virosomes Lipid vesicle containing
inactivated viral proteins
Virosomal-adjuvanted influenza vaccine (Inflexal®V)
increases antibody titer (11).
Influenza, Hepatitis A
NLRP3, nucleotide binding domain-like receptor protein 3; DCs, dendritic cells; HBV, Hepatitis B virus; HPV, human papillomavirus; MPL, monophosphoryl lipid; LN, lymph node.
molecules (33, 34). A comprehensive overview of these and
alternative cross-presentation pathways in DCs has recently been
reviewed (35).
How antigens are transported from the endosomes to the
cytosol is still under debate. Extensive studies in murine models
identified the ER-associated degradation (ERAD)member, Sec61,
as a possible translocator for antigen from the endosomes into
the cytosol. Applying a Sec61-specific intracellular antibody,
Zehner et al. showed that they could trap Sec61 in the ER
and prevent its transport toward endosomes, thereby blocking
antigen translocation and cross-presentation (36). However, a
more recent study using mycolactone, which binds specifically
to Sec61α, showed severe inhibition of protein import into the
ER but no inhibition of ERAD or protein export from endocytic
compartments (37). Although, both studies showed inhibition
of DC cross-presentation upon blocking of Sec61, it seems
that Sec61 plays a more dominant role in inhibiting protein
translocation into the ER and altering antigen cross-presentation
at a different level than antigen export to the cytosol.
Another ongoing debate is how ER proteins are translocated
to endosomes in DCs for efficient cross-presentation. The
group of Amigorena proposed that recruitment of ER and
ER-Golgi intermediate compartment (ERGIC) components to
phagosomes is mediated by the ER-resident SNARE Sec22b
(38). Silencing of Sec22b uncovered that phagosome-lysosome
interactions were delayed, thereby limiting proteolysis and
preserving antigenic fragments for cross-presentation, which
was recently also confirmed in conditional Sec22b-knockout
DCs (39). Conflicting results were found using similar Sec22b-
knockout DCs (40) and based on a review of both studies
with respect to technical differences, a role for Sec22b as well
as for unidentified new regulators of cross-presentation was
suggested (41). Although Sec22b seems to regulate antigen cross-
presentation in the vacuolar pathway, it is not ruled out that it
can play a role in the cytosolic pathway.
Two recent studies report on regulation of antigen cross-
presentation in DCs by stromal interaction molecule 1 (STIM1),
a calcium sensor that conveys the calcium content of the
ER to store-operated channels of a cell (42, 43). Nunes-
Hasler and colleagues showed that STIM1 can promote the
contact sites between the ER and phagosomes (42). This
induces Ca2+ signaling and thereby the migration and fusion
of phagosomes with endosomes or lysosomes to enable efficient
cross-presentation in DCs. In a companion study it was shown
that the ER membrane protein uncoordinated 93 homolog
B1 (UCN93B1) interacts with STIM1 and can control cross-
presentation in DCs (43). Ablation of UCN93B1 impairs phago-
lysosomal fusion, proteolytic activity, and antigen export to
the cytosol, resulting in a decrease of antigen degradation and
cross-presentation. Others showed that antigen transportation
into the cytosol is enhanced by NADPH-oxidase complex
(NOX2) and reactive oxygen species (ROS) production in
the endosomes (44). Reactive oxygen species causes lipid
peroxidation, which disrupts the endosomalmembrane, resulting
in antigen leakage from endosomes. Furthermore, it has been
shown that NOX2 can be recruited to the endosomes to induce
alkalization upon ROS release (45). This will cause an increase
of endosomal pH thereby preventing rapid antigen degradation,
resulting in enhanced antigen cross-presentation. The group of
Guermonprez suggested that lipid bodies (LBs) are involved in
DC cross-presentation (46). They showed that the Immunity-
related GTPase family member 3 (Irgm3) controls accumulation
of LBs induced by cell activation stimuli including INF-γ and
Poly(I:C). LBs are organelles composed of a central core of
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cholesteryl esters and triglycerides that are surrounded by a single
layer of phospholipids also containing LB proteins (47). The
Irgm3 protein is localized in the ER and in LBs where it interacts
with the LB coat protein adipose differentiation-related protein
(ADRP). Mice deficient in either Irgm3 or ADRP showed defects
in LB formation and impaired cross-presentation inDCs. Further
research is needed to understand how LBs control antigen cross-
presentation by DCs and to determine the molecular pathways
that control the involvement of LBs.
ANTIGEN CROSS-PRESENTATION AND DC
SUBSETS
An important aspect to take into account when choosing an
adjuvant to induce DC cross-presentation is the type of DC that
will be affected. Intensive research has shown that there are many
DC subsets present in mice as well in human, with still room for
newly unidentified subsets. Murine DCs in secondary lymphoid
organs can be divided roughly into conventional DCs (cDCs)
and plasmacytoid DCs (pDCs). cDCs can be further divided
into cDC1 (CD8α+ and CD103+) and cDC2 (CD8α−, CD11b+,
and CD172a+) DCs (48). The development of CD8α+ DCs is
regulated by the transcription factors including inhibitor of DCN
binding 2 (Id2), interferon regulatory factor (IRF) 8, basic leucine
zipper ATF-like 3 transcription factor (BATF3), and the nuclear
factor interleukin 3 regulated (NFIL3) (49). The development of
CD8α− DCs is orchestrated by the transcription factors including
RelB, NOTCH2, RBP-J, IRF2, and IRF4. Deletion of either of
these genes can lead to developmental defects of the DC subsets.
Mice in which a given DC subset has been selectively depleted,
e.g., Batf3−/− mice or zinc finger transcription factor knockout
studies, have provided important insight in the functional
role of DC subsets in antigen presentation (50, 51). However,
the interpretation of the data in these mice regarding cross-
presentation is not always straightforward due to incomplete
depletion, depletion associated side effects, and DC cross-
talk. In general, CD8α+ DCs are considered to be the most
potent cross-presenting subset of antigens including proteins,
antibody-bound-, cell-associated, and other types of antigens
in vivo and ex vivo (50, 52–55). The explanations for the
superior cross-presentation ability of CD8α+ DCs include lower
degradation of antigen in endosomes by ROS production (56),
more efficient transfer of exogenous antigens into the cytosol
(57), and higher expression of components that are associated
with MHCI processing pathway (55). Emerging data, however,
suggest that the cross-presenting ability of each DC subset is
tuned by and dependent on factors such as DC location and
activation status, the type of antigen, and local inflammatory
signals (58). Indeed, the main DC subset responsible for cross-
presentation in lung, intestine and skin is the migratory CD103+
DCs (59, 60). Although CD8α− DCs are generally considered to
be the most potent MHCII antigen presenting subset to CD4+
T cells, it has been shown that CD8α− DCs can efficiently
cross-present antibody-bound antigen, antigens from Salmonella
typhimurium and S. cerevisiae, or antigen in the presence of
saponin adjuvants (61–65). CD8α− DCs have been shown to
cross-present antibody-bound antigen efficiently after activation
of Fcγ-receptors (66), but a more recent study showed that
complement factor C1q plays a dominant role in antibody-bound
antigen uptake and cross-presentation in DCs (67). Although,
some studies have shown the ability of pDCs to cross-present in
vitro or ex vivo (34, 68, 69), their role in cross-presentation in
vivo seems lacking during viral infections despite the fact that
they are known for their ability in producing large amounts of
type I interferons (70, 71). However, a recent study showed that
upon TLR ligand activation, mitochrondial ROS production is
increased independently of NOX2 in pDCs (72). Increased ROS
production resulted in high endosomal pH, antigen protection
from endosomal degradation, and induced export to the cytosol,
ultimately leading to enhanced antigen cross-presentation and
CD8+ T cell priming.
In human, the cDC subset in blood can roughly be divided
into BDCA1+ (CD1c+) and BDCA3+ (CD141+) DCs (73). The
BDCA1+ and BDCA3+ subsets are proposed as the human
counterparts of murine CD8α− and CD8α+ DCs, respectively.
It has been shown that BDCA1+ DCs are capable of cross-
presentation of extracellular antigen (74). Upon activation with
TLR ligands, BDCA1+ DCs showed similar efficiency in cross-
presentation compared to BDCA3+ DCs (75). A recent study
showed that in vivo generated monocyte-derived DCs (moDCs)
and monocyte-derived macrophages can both cross-present
efficiently in a vacuolar-dependent pathway (76). In contrast
to murine pDCs, the human counterpart has been reported
to cross-present soluble, cell-associated antigen efficiently (77).
However, recent work by the group of Ginhoux has identified a
pre-DC subset that bears the classical pDC markers, including
CD123, CD303, and CD304 (78). This pre-DC subset can be
distinguished from the classical pDCs by additional markers,
such as CD33, CX3CR1, CD2, CD5, and CD327. Importantly,
they showed that only pre-DCs could induce CD4+ T cell
proliferation and IL-12 production compared to classical pDCs.
These data imply that the antigen presenting ability of pDCs
might be a result of “contaminating” pre-DCs. Whether these
pre-DCs can also cross-present to CD8+ T cells is currently
unknown. It will be important to use additional markers to isolate
pure pDC subset for future analysis of their antigen presenting
capacity.
So far, most of the aforementioned studies investigating the
molecular mechanisms of antigen cross-presentation make use
of murine DC model systems and require confirmation in the
human DC setting. Nevertheless, it seems that choosing specific
antigen targeting routes can determine the outcome of DC
cross-presentation efficiency of different subsets. Deciphering the
molecular mechanisms of cross-presentation in the different DC
subtypes in mice and human is needed for the optimal design of
therapeutic vaccines.
CLINICALLY RELEVANT ADJUVANTS AND
ANTIGEN CROSS-PRESENTATION
During the last years, many groups have been developing
adjuvants that facilitate uptake by APCs, protect antigens against
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degradation and stimulate strong immune memory responses
(79). Here, we will focus on new insights in the mode of action
of clinically relevant adjuvants on antigen cross-presentation
by DCs and subsequent induction of cellular immunity. Many
studies analysing adjuvants show an enhancement of CD8+ T
cells, but most studies do not differentiate between enhanced
antigen cross-presentation by DCs or enhanced DC maturation,
e.g., expression of co-stimulatory molecules and cytokines.
Therefore, we will elaborate on those studies that describe
the mechanisms of cross-presentation induced by adjuvants,
including the involvement of the cytosolic and vacuolar pathway
of cross-presentation in DCs. In addition, we will focus
on clinically relevant adjuvants, including aluminum-based
nanoparticles, saponin-based adjuvants (including ISCOMs),
and TLR ligands.
Aluminum-Based Nanoparticles
Aluminum salts are the most widely applied adjuvants in human
vaccines and it is firmly established that they are safe and well-
tolerated. Aluminum oxyhydroxide [AlO(OH)] is a positively
charged vaccine carrier that strongly absorbs negatively charged
antigens (80, 81). Its mechanisms of action include antigen
retention and local inflammation via activation of the NLRP3.
Either direct phagocytosis of the adjuvant or phagocytosis of
stressed or dying cells that contain the aluminum salts and
subsequent release of damage associated molecular patterns are
able to activate the NLRP3 inflammasome (82). Aluminum
adjuvants induce the production of IL-1β and IL-18 by DCs and
a strong default Th2 differentiation promoting the production
of antibodies (83). Therefore, current aluminum-based adjuvants
exhibit a very limited potency to induce a cellular Th1 immune
response as compared to other adjuvants (84).
Interestingly, Jiang et al. transformed the micrometer-sized
aggregates of AlO(OH) adjuvant into nano-sized vaccine carriers
by shielding its positive charge with a polyethylene glycol
(PEG)-containing polymer (80). The resulting nanoparticles
could be readily co-loaded with both antigen and the TLR
ligand CpG without affecting size or Zeta-potential of the
particles and these particles were effectively internalized by
murine APCs. Using endocytic pathway inhibitors, they showed
that internalization is highly dependent on scavenger receptor
A-mediated endocytosis (Illustrated in Figure 1). Confocal
microscopy revealed localization of the nanoparticles within
the lysosomes as well as in the cytosol, indicating lysosomal
escape. The cytosolic delivery of the nanoparticles is possibly
caused by AlO(OH) induced destabilization of lysosomes as
described previously by others (88). Most importantly, Jiang et al.
showed that cytosolic delivery of the nanoparticles containing
OVA protein effectively promotes cross-presentation by DCs
compared to free OVA protein, as measured by a monoclonal
antibody specifically detecting MHCI/OVA peptide complexes.
Strikingly, the presence of CpG in the nanoparticle further
enhanced the level of antigen cross-presentation by DCs.
Further analysis revealed that brefeldin A, which inhibits protein
transport from the ER to Golgi, and MG-132, which inhibits the
proteasome, reduced DC cross-presentation, while the cysteine
protease inhibitor leupeptin did not. These data are thus
consistent with the cytosolic route being the dominant cross-
presentation pathway activated by the nanoparticle. Interestingly,
while the size and positive charge at neutral pH of AlO(OH)
in the traditional vaccine prevented its targeting to lymph
nodes, AlO(OH) packed into nanoparticles of <90 nm in
diameter efficiently reached lymph node APCs in vivo. Especially,
nanoparticles loaded with CpG were able to expand and mature
DCs in the lymph nodes and induced production of TNF-α
and IL-12p70. Moreover, the presence of CpG in the AlO(OH)
nanoparticles was necessary for the effective induction of both
IgG1 and IgG2 responses as well as strong CD8+ T cell
response and delayed growth of B16 melanoma tumors. Control
vaccination with CpG and OVA antigen without the AlO(OH)
nanoparticles was much less effective. In conclusion, AlO(OH)
nanoparticles in combination with CpG is a very potent and
promising adjuvant combination for the induction of cellular
immune responses.
Two other studies using AlO(OH) adjuvant packed into
nanoparticles confirm this is a promising strategy to promote
cross-presentation and/or cross-priming. Dong et al. synthesized
AlO(OH) nanoparticles containing a polyethyleneimine (PEI)
modification to increase antigen loading capacity (89). Particles
were successfully loaded with tumor autophagosome derived
proteins that are potentially enriched for tumor associated
antigens. Zhao et al. created Al2O3 nanoparticles containing
the Vx3 ubiquitin binding protein to enrich for ubiquitinated
proteins present in tumor lysates, also to potentially enrich for
tumor associated antigens (90).
Thus, the application of aluminum-based adjuvants showed
that the use of aluminum salts can be improved by using nano-
sized particles, especially in combination with TLR ligands, and
that cross-presentation by DCs can be enhanced. The AS04
adjuvant is clinically approved, and is a combination of MPL
and aluminum salt (Table 1). AS04 has shown to be very potent
and the aluminum hydroxide is able to prolong the MPL induced
cytokine response. The fact that this vaccine is successfully used
in the clinic demonstrates that aluminum can be a useful carrier
of other immunostimulatory molecules and that combining
adjuvants is a promising strategy for the induction of strong
cellular immune responses.
Saponin-Based Adjuvants
Saponins are triterpene glycosides derived from the bark of the
South American soapbark tree,Quillaja saponaria. Dalsgaard has
obtained a heterogeneous mixture of soluble Quillaja-derived
saponins, Quil-A R©, which has been commercialized and used in
veterinary studies showing humoral and cellular immunity (91,
92). Further, purification of this mixture led to the identification
of 10 fractions containing adjuvant activity, includingQS-21 (93).
Since QS-21 showed the least hemolytic effect compared to the
other fractions, it was extensively investigated as an adjuvant.
QS-21 can induce a robust antibody and cell-mediated immune
response activating both Th1 and CD8+ T cells (94). QS-21
has been proposed to exert its immunomodulatory effects by
acting on different cell types in vivo [reviewed in (95)]. One
study has shown that QS-21 can activate NLRP3 inflammasomes
to induce IL-1β and IL-18 production in murine DCs (96).
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FIGURE 1 | Models for antigen cross-presentation mechanisms induced by adjuvants in DCs. TLR-based adjuvants: In the presence of TLR triggering, antigen is
taken up by the DCs and delivered to phago/lysosomes (1). The MHCI molecules and TLR4 within the endosomal recycling compartment are shuttled into the
phago/lysosome (2a) following TLR4 signaling induced phosphorylation of SNAP23 (85). TLR4 signaling further induces perinuclear clustering (3) of lysosomes in a
(Continued)
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FIGURE 1 | Rab34-dependent manner (86), resulting in delayed (dashed line) phago-lysosomal fusion (2b). The latter slows down antigen degradation and thereby
increases cross-presentation. Saponin-based adjuvants: Saponins, alone or in phospholipid and cholesterol particles, in combination with antigens are phagocytosed
(A). The saponins induce lipid bodies (B) and increase cytosolic translocation of the antigen (C) and subsequent proteasome-dependent cross-presentation (D)
(65, 87) via the cytosolic pathway. Lipid bodies play an unknown but crucial role in this process (B) (65). Aluminum-based nanoparticles: An aluminum-based
nanoparticle loaded with antigen and the TLR9 ligand CpG is taken up via endocytosis, which is largely mediated through the scavenger receptor A (I) (80). After
lysosomal fusion with the endosome, nanoparticle-mediated rupture of the vesicular membrane gains antigens access to the cytosol (II) and after proteasomal
degradation (III) are cross-presented via the cytosolic pathway.
However, NLRP3-deficient mice showed higher levels of Th1
and Th2 antigen-specific T cell responses and increased IgG1
and IgG2c in the presence of QS-21, thus suggesting a more
complex regulatory role for NLRP3. In human moDCs QS-21
has been reported to facilitate non-receptor-mediated uptake
of exogenous antigen in a cholesterol-dependent manner (87).
After endocytosis of antigen and QS-21, both are transported
to the lysosomes where QS-21 causes lysosomal destabilization,
followed by antigen release in the cytosol for further processing
and cross-presentation (Illustrated in Figure 1). Moreover, they
showed that cell activation depends on the activity of Syk kinase
and cathepsin B, since Syk knockdown blocked NF-κB activation
and cytokine production (IL-6 and TNF) in moDCs and shRNA-
mediated knockdown of cathepsin B strongly decreased the
expression of both TNF and IL-6 mRNAs. Moreover, cathepsin
B-deficient mice showed lower cytokine (IL-2, TNF, and IFN-
γ)-producing antigen-specific T cells. Neither for human nor
for murine DCs has the mode of action of QS-21 on DC cross-
presentation efficiency been investigated in detail.
When Quillaia saponins are admixed with cholesterol and
phospholipid they spontaneously form open cage particles
with a diameter of ∼40 nm, termed immune stimulating
complexes (ISCOMs) (97). Due to the interaction of saponin
with cholesterol, saponin is thought to be protected from
hydrolysis and thereby stabilizing the adjuvant (98). Moreover,
toxic side effects are greatly reduced since saponin interaction
with membranes is decreased (99), while induction of antigen-
specific T cell responses, prolonged antibody responses, and a
balanced Th1/Th2 immunity are equal or even more potent
(100, 101). In this review we will address the different saponin
formulations as saponin-based adjuvants (SBAs).
Duewell et al. showed that SBA vaccines injected
subcutaneously in mice resulted in the recruitment and
activation of innate and adaptive immune cells in vaccine
site-draining lymph nodes. They showed efficient uptake
of antigen in DCs, induction of DC maturation, and IL-12
production in vivo (102). Moreover, they showed enhanced
antigen cross-priming by CD8α+ murine DCs relative to antigen
alone, measured by induction of T cell proliferation, as well
as protective anti-tumor immunity. The SBA vaccine induced
activation and MHCI cross-priming by DCs in murine draining
lymph nodes in a TLR-signaling adapter MyD88-independent
manner (64). On the contrary, CD8+ T cell-priming, NK cell
activation, and potent antitumor activity in a prophylactic tumor
challenge model in vivo were MyD88-dependent, suggesting a
more downstream role of MyD88. They further showed that SBA
induced efficient cross-priming by both CD8α− CD205+ DCs as
well as CD8α+ CD205+ DCs in draining lymph nodes 24 hours
after vaccination. Surprisingly, murine splenic CD4+ DCs were
more efficient than CD8α+ DCs at cross-priming soluble antigen
formulated with SBA. Studies using another SBA formulation
called Matrix-MTM, which consists of two individually formed
particles, Matrix-A and Matrix-C, together with cholesterol and
phospholipid, also showed an increase in CD8+ and CD4+ T
cell responses and 100% protection in a lethal viral challenge
murine model (103). However, the precise mechanism how T
cell induction was achieved was not investigated.
Two recent papers provide more insight in the mechanism
of SBA induced cross-presentation by DCs. They demonstrated
that saponin fraction C alone or formulated as an SBA can
both induce an unprecedented level of DC cross-presentation
in murine GM-CSF generated DCs in vitro, as shown by
activation of the co-stimulation independent B3Z reporter T-
cell line (47, 65). Moreover, SBA encounter did not change
levels of CD80 or CD86 on in vitro cultured murine DCs. They
further demonstrated that SBA predominantly act by inducing
cross-presentation in the monocytic CD11b+ DC subset in
vitro and in vivo, a population distinct from the well-described
CD8α+ cross-presenting DCs. The presence of SBA increased
cytosolic translocation of antigen, resulting in proteasome-
dependent cross-presentation. Strikingly, specifically in this
monocytic CD11b+ DC subset, SBA enhanced DC cross-
presentation by lipid body induction. Both pharmaceutical and
genetic interference with lipid body formation inhibited the SBA-
induced cross-presentation in these DCs in vitro and in vivo
(Illustrated in Figure 1).
Human moDC studies have shown that SBA induced efficient
cross-presentation of the cancer testis antigen NY-ESO-1 based
on IFN-γ production by CD8+ T cells (101). Interestingly, NY-
ESO-1/SBA cross-presentation was studied for three distinct
HLA-restricted epitopes. Independent of whether NY-ESO-
1 is delivered in combination with SBA as two separate
entities or formulated into one particle (ISCOMATRIX), the
generation of two epitopes (HLA-A2, HLA-Cw3) was proteasome
independent while the generation of the third epitope was highly
proteasome dependent, as was the processing of the melanoma-
differentiation antigen Melan-A when combined with SBA.
Further analysis uncovered that cytosolic tripeptidyl peptidase II
(TPPII) was involved in the generation of the HLA-A2, HLA-
Cw3 epitopes of the NY-ESO-1/SBA vaccine. In line with this
finding, they showed rapid antigen translocation from lysosomes
into the cytosol in the presence of SBA. Thus, SBA vaccines
are compatible with both cytosolic TPPII and the proteasome
to generate immunogenic epitopes for MHCI antigen cross-
presentation. In a follow-up study they showed that in vitro
generated moDCs and freshly isolated CD1c+ DCs from blood
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could both cross-present NY-ESO-1 andMelan-A epitopes (104).
However, when the antigen was limited, moDCs were more
efficient than CD1c+ DCs in cross-presentation in vitro. In
addition, under these conditions physically incorporating the
antigen into SBA (ISCOMATRIX) was superior compared to
separate administration of antigen and adjuvant to CD1c+ DCs.
In conclusion, also in human DCs, SBAs can efficiently induce
DC cross-presentation and different epitopes from the same
protein can be processed by different pathways in DCs.
Currently, only the saponin QS-21 is approved for use in
formulation with MPL as AS01 adjuvant in a human vaccine
against malaria (Table 1). Furthermore, QS-21 has been added
as adjuvant to a recombinant retroviral subunit vaccine against
feline leukemia virus (105) in cats. In the human setting, SBAs in
combination with NY-ESO-1 protein have now also been used
in human clinical trials in patients with NY-ESO-1+ tumors,
generating high-titer antibody responses, and strong CD8+ and
CD4+ T cell responses (106). To further extend the clinical
application of SBAs, it will be important to fully understand
the mode of actions of the adjuvant on cross-presentation by
different DC subsets, including the role of lipid body induction.
In addition, defining saponin adjuvant antigen formulations
showing limited side effects while inducing maximal antigen
cross-presentation capacity should further pave the way for their
clinical application.
TLR Ligands
TLR ligands are well-known for their ability to induce DC
maturation resulting in expression of co-stimulatory molecules
and pro-inflammatory cytokines. The capacity to induce potent
cellular immunity makes them a powerful addition to the
armamentarium for cancer vaccinations. Interestingly, recent
studies show that TLR ligands can also have direct effects on
cross-presentation by DCs, making TLR ligands even more
attractive for use in cancer vaccines. Upon TLR4-induced DC
maturation, cross-presentation is first enhanced and followed
by down-modulation of antigen internalization and cytosolic
delivery (107). The two following studies focus on the first
hours following TLR4 activation, in which the cross-presentation
capacity is increased (85, 86).
Nair-Gupta et al. described a new pathway, in which TLR
signaling, especially TLR4 triggering, can lead to increased
cross-presentation by murine DCs (85). They showed that
Escherichia coli expressing OVA protein (E. coli-OVA) is able
to induce cross-priming of CD8+ T cells by wildtype DCs,
but not by Trif−/−MyD88−/− DCs. Trif−/−MyD88−/− DCs
could induce CD8+ T cell priming when provided with the
pre-processed SIINFEKL epitope, thereby excluding a general
inability to activate T cells. Confocal microscopy analysis
showed the selective accumulation of MHCI molecules within
the LAMP1+ phagosomes also carrying the TLR4 ligand.
These MHCI molecules were shown to be derived from
the perinuclear Rab11a+ vesicle-associated membrane protein
(VAMP)3/cellubrevin+ and VAMP8/endobrevin+ endosomal
recycling compartment (ERC) which contains large amounts
of MHCI. Silencing Rab11a dissolved the existence of the
perinuclear reserves of MHCI and diminished TLR-mediated
cross-presentation. Of note, these Rab11a+ MHCI+ pools are
predominantly found in the CD8α+ DCs, suggesting that the
existence of MHCI pools contributes to their strong cross-
presentation capacity. Trafficking of MHCI from the ERC to
the phagosome is, however, Rab11a independent but controlled
by TLR4 induced IKK2-dependent phosphorylation of SNAP23.
In conclusion, TLR signaling, especially via TLR4 leads to
phosphorylation of SNAP23 and SNAP23-mediated trafficking
of the perinuclear MHCI pools from the ERC to the LAMP1+
TLR ligand+ phagosomes (Illustrated in Figure 1). Alloatti et al.
uncovered anothermechanism how LPS treatment of DCs results
in improved cross-presentation of both soluble and bead-bound
OVA protein as well as proliferation and activation of antigen
specific CD8+ T cells in vitro and in vivo (86). By single organelle-
based flow cytometry they showed that upon LPS stimulation,
phagosomes contained more OVA protein and expressed less
LAMP1, indicating less antigen degradation and lower levels of
phago-lysosomal fusion, respectively. This effect was completely
dependent on TLR4. Liquid chromatography-tandem mass
spectrometry analysis of phagosomal proteins of both resting
DCs and LPS stimulated DCs showed that phagosomes of
resting DCs were highly enriched for the majority of lysosomal
hydrolases, consistent with the LPS induced reduction in phago-
lysosomal fusion. Moreover, LPS induced perinuclear clustering
of LAMP1+ lysosomes in maturing DCs, while broad peripheral
distribution was observed in unstimulated DCs. This same
perinuclear clustering was previously seen by Nair-Gupta et al.
upon TLR stimulation (85). The perinuclear accumulation of
lysosomes delayed phagosome maturation and phago-lysosomal
fusion, resulting in improved cross-presentation, which was
controlled by the GTPase Rab34 (Illustrated in Figure 1). Rab34
has been previously linked to cross-presentation efficiency (108).
Interestingly, TLR7 and TLR9 activating ligands were able
to show similar effects, but to a lower extent. Since antigen
degradation is not mediated through the proteasome and loading
of MHCI molecules with antigen does not happen in the ER
but in the phago/lysosome, we believe the vacuolar pathway is
followed.
TLR9 ligand CpG has potent immunostimulatory adjuvant
activity and preferentially induces Th1 responses and tumor-
specific CD8+ T cells (109, 110). As TLR9 is located
intracellularly, CpG needs to be internalized to exert its
immunomodulatory effect. Consistent with the aforementioned
findings, the cross-priming ability of murine DCs was shown to
be dependent on the colocalization of antigen and TLR9 ligand
in the same endocytic compartment within DCs (111, 112).
Indeed, the failure or success of CpG as an adjuvant in the
tumor setting was dependent on the timing of CpG relative to
the release of tumor antigen following ablation (111). Similarly,
combining TLR ligand and antigen in the same vaccine particle
is more potent compared to separate administration (112). Thus,
addition of a TLR ligand as an adjuvant to a vaccine is a promising
treatment strategy to induce both enhanced cross-presentation
and cross-priming by DCs.
In summary, since their discovery a lot of knowledge has been
acquired regarding the mode of action of TLRs and their ligands,
including their role in antigen cross-presentation. Many TLR
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ligands have now also been tested as adjuvants for therapeutic
cancer vaccines in clinical trials. However, only MPL has been
approved as a purified TLR ligand for clinical use in several
adjuvants (Table 1) (113). It will be interesting to test MPL as well
as other TLR ligands in clinical development for their capacity to
induce antigen cross-presenting in human DC subsets for future
clinical application.
FUTURE PERSPECTIVES
For vaccines aiming to induce cell-mediated immunity such
as cancer vaccines, it is important they stimulate both antigen
cross-presentation by DCs and DC maturation to initiate an
optimal CD8+ T cells response. The “ideal” adjuvant thus
combines both these characteristics and is able to prolong
antigen exposure to the immune system. SBAs stand out to
enhance DC cross-presentation, but are relatively poor in
immune activation. Therefore, additional DC activation by e.g.,
TLR ligands is crucial. Moreover, combination of multiple
PRR agonists can induce synergistic effects on DC activation
(114). Furthermore, activating both the vacuolar and cytosolic
pathway might be beneficial to enhance DC cross-presentation.
To achieve prolonged antigen exposure another type of adjuvant
formulation might be required. Based on pre-clinical as well
clinical data, a picture is emerging that an optimal vaccine
adjuvant may actually require a combination of adjuvants rather
than a single adjuvant entity. The clinically approved vaccines
adjuvants AS01, AS02, and AS04 show that a combination of
different adjuvants, especially TLR ligands combined with other
adjuvant(s) such as saponins or alum, can be both potent and safe
to use in the clinic.
An important aspect to consider when choosing an adjuvant
is that different DC subsets show differential cross-presentation
efficiencies, which makes it important to study the response
in subsets and potentially even to specifically target the most
effective subsets. Targeting antigens directly to DCs using
antibodies is explored for better antigen uptake, DC activation
and thereby T cell-mediated immunity. Moreover, directly
targeting specific DC subsets or receptors that allow strong
cross-presentation can further enhance immune responses.Many
studies targeting C-type lectin receptors on DCs including
DEC205, DC-SIGN, and DNGR1 (Clec9A) showed efficient
antigen-specific CD8+ T cell responses (115). A potential
drawback of (too) specific DC targeting is that in vivo the
different DC subsets are known to work in concert and
that antigen presentation by different DC subsets during the
course of an immune response may be important to unleash
a powerful immune response. Also vaccines with a different
design, that are beyond the scope of this review, showed
promising results, including the work of Sahin et al. (116,
117). Vaccines consisting of RNA encoding tumor antigen
derived epitopes and containing immunostimulatory motifs were
delivered by nano-sized lipoplexes that preferentially target
and activate DCs in the spleen and have already been tested
in a few patients. It is important to realize that so far,
most of the studies looking into the potency and mode of
action of adjuvants use murine DCs and hardly differentiate
between different DC subsets. Extrapolation of the murine
data on adjuvants to human DCs and preferentially also
DC subsets will be important for future clinical application.
It may be especially rewarding to test adjuvants in clinical
development for their capacity to induce antigen cross-
presenting by human DCs to select for adjuvants inducing
T cell-mediated immunity. In conclusion, many aspects, from
choosing the antigen, targeting specific DC subsets, activating
DCs via PRR signaling, to stimulating efficient DC cross-
presentation, need to be considered when choosing a vaccine
and adjuvant. Understanding the underlying mechanisms will
boost the development of next generation vaccines for clinical
application.
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